{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:56:49Z","timestamp":1761893809419},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2003,1]]},"DOI":"10.1053\/shem.2003.50030","type":"journal-article","created":{"date-parts":[[2003,4,7]],"date-time":"2003-04-07T20:38:49Z","timestamp":1049747929000},"page":"22-25","source":"Crossref","is-referenced-by-count":8,"special_numbering":"S1","title":["Indications for lowering platelet numbers in essential thrombocythemia"],"prefix":"10.1053","volume":"40","author":[{"given":"Tiziano","family":"Barbui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/shem.2003.50030_bib1","first-page":"348a","article-title":"Epidemiological, diagnostic, therapeutic, and prognostic aspects of pf essential thrombocythemia in a retrospective study of the GIMMC group in 2000 patients","volume":"90","author":"Gugliotta","year":"1997","journal-title":"Blood"},{"key":"10.1053\/shem.2003.50030_bib2","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1055\/s-0038-1657600","article-title":"Therapeutic dilemmas: Balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD)","volume":"78","author":"Murphy","year":"1997","journal-title":"Thromb Hemost"},{"key":"10.1053\/shem.2003.50030_bib3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2141.2000.02188.x","article-title":"Second malignancies in patients with essential thrombocythemia treated with busulfan and hydroxyurea: Long-term follow-up of a randomized clinical trial","volume":"110","author":"Finazzi","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1053\/shem.2003.50030_bib4","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/0277-5379(83)90091-3","article-title":"Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: Relationship to platelet number and function","volume":"9","author":"Barbui","year":"1983","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1053\/shem.2003.50030_bib5","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","article-title":"Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia","volume":"8","author":"Cortelazzo","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1053\/shem.2003.50030_bib6","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1002\/1097-0142(19910601)67:11<2926::AID-CNCR2820671136>3.0.CO;2-3","article-title":"Thrombotic and hemorrhagic complications in thrombocythemia. A retrospective study of 103 patients","volume":"67","author":"Colombi","year":"1991","journal-title":"Cancer"},{"key":"10.1053\/shem.2003.50030_bib7","first-page":"172","article-title":"Risk-based management in essential thrombocythemia. The American Society of Hematology Education Program Book","author":"Tefferi","year":"1999"},{"key":"10.1053\/shem.2003.50030_bib8","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essentiul thrombocythemia and a high risk for thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1053\/shem.2003.50030_bib9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/(SICI)1096-8652(199605)52:1<42::AID-AJH7>3.0.CO;2-6","article-title":"Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"52","author":"Nand","year":"1996","journal-title":"Am J Hematol"},{"key":"10.1053\/shem.2003.50030_bib10","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V91.2.616","article-title":"Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p depletion","volume":"91","author":"Sterkers","year":"1998","journal-title":"Blood"},{"issue":"suppl 4","key":"10.1053\/shem.2003.50030_bib11","first-page":"6","article-title":"Interferon in the treatment of myeloproliferative disorders","volume":"27","author":"Silver","year":"1990","journal-title":"Semin Hematol"},{"key":"10.1053\/shem.2003.50030_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1600-0609.1990.tb00899.x","article-title":"Therapy of essential thrombocythemia with alpha-interferon: Results and prospects","volume":"52","author":"Lazzarino","year":"1990","journal-title":"Eur J Haematol"},{"key":"10.1053\/shem.2003.50030_bib13","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/BF01703444","article-title":"Interferon alpha-2b in the long-term treatment of essential thrombocythemia","volume":"63","author":"Sacchi","year":"1991","journal-title":"Ann Hematol"},{"key":"10.1053\/shem.2003.50030_bib14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2141.1991.tb08118.x","article-title":"Interferon in essential thrombocythemia","volume":"79","author":"Gisslinger","year":"1991","journal-title":"Br J Haematol"},{"key":"10.1053\/shem.2003.50030_bib15","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1055\/s-2007-996123","article-title":"Interferon-alpha therapy in polycythemia vera and essential thrombocythemia","volume":"23","author":"Elliott","year":"1997","journal-title":"Semin Thromb Hemost"},{"key":"10.1053\/shem.2003.50030_bib16","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1205::AID-CNCR21>3.0.CO;2-8","article-title":"Long-term treatment of myeloproliferative disease with interferon-alpha 2b","volume":"83","author":"Gilbert","year":"1998","journal-title":"Cancer"},{"key":"10.1053\/shem.2003.50030_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0002-9343(92)90017-6","article-title":"Anagrelide, a therapy for thrombocythemic states: Experience with 577 patients","volume":"92","author":"Anagrelide Study Group","year":"1992","journal-title":"Am J Med"},{"issue":"suppl 2","key":"10.1053\/shem.2003.50030_bib18","first-page":"23","article-title":"Treatment of essential thrombocythemia with anagrelide","volume":"36","author":"Silverstein","year":"1999","journal-title":"Semin Hematol"},{"key":"10.1053\/shem.2003.50030_bib19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/(SICI)1096-8652(199711)56:3<168::AID-AJH6>3.0.CO;2-W","article-title":"Thrombotic complications in essential thrombocythemia with relatively low platelet counts","volume":"56","author":"Regev","year":"1997","journal-title":"Am J Hematol"},{"key":"10.1053\/shem.2003.50030_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2141.1998.00529.x","article-title":"Should a platelet count of 600 \u00d7 109\/L be used as a diagnostic criterion in essential thrombocythemia? An analysis of the natural course including early stages","volume":"199","author":"Lengfelder","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1053\/shem.2003.50030_bib21","first-page":"492","article-title":"Diagnosis of essential thrombocythemia in platelet counts between 400 and 600 \u00d7 109\/L","volume":"85","author":"Sacchi","year":"2000","journal-title":"Haematologica"},{"key":"10.1053\/shem.2003.50030_bib22","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V97.4.863","article-title":"Long-term use of anagrelide in young patients with essential thrombocythemia","volume":"97","author":"Storen","year":"2001","journal-title":"Blood"},{"key":"10.1053\/shem.2003.50030_bib23","first-page":"20a","article-title":"The effects of anagrelide on human megakaryocytopoiesis","volume":"7","author":"Solberg","year":"1989","journal-title":"Blood"},{"key":"10.1053\/shem.2003.50030_bib24","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood.V79.8.1931.1931","article-title":"Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans","volume":"79","author":"Mazur","year":"1992","journal-title":"Blood"},{"key":"10.1053\/shem.2003.50030_bib25","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2165\/00003495-199447050-00007","article-title":"Anagrelide: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of thrombocythemia","volume":"7","author":"Spencer","year":"1994","journal-title":"Drugs"},{"key":"10.1053\/shem.2003.50030_bib26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1055\/s-2007-996112","article-title":"Anagrelide as a new platelet-lowering agent in essential thrombocythemia: Mechanism of action, efficacy, toxicity, current indications","volume":"23","author":"Tefferi","year":"1997","journal-title":"Semin Thromb Hemost"},{"issue":"suppl 2","key":"10.1053\/shem.2003.50030_bib27","first-page":"14","article-title":"Clinical parameters for determining when and when not to treat essential thrombocythemia","volume":"36","author":"Barbui","year":"1999","journal-title":"Semin Hematol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196303807072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196303807072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T17:04:20Z","timestamp":1704819860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196303807072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":27,"alternative-id":["S0037196303807072"],"URL":"https:\/\/doi.org\/10.1053\/shem.2003.50030","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2003,1]]}}}